CrystalBioScience

Crystal Bioscience is a biotechnology company that pioneered the use of transgenic avian platforms for the discovery of human monoclonal antibodies. Its flagship technology, the OmniChicken, enables the generation of antibodies against highly conserved human targets that are often immunologically silent in traditional rodent models. By utilizing the evolutionary divergence of birds, the platform provides a unique and diverse antibody repertoire suitable for challenging therapeutic targets such as G protein-coupled receptors and ion channels. The company was acquired by Ligand Pharmaceuticals in 2017 and its technology now forms a core component of the OmniAb discovery platform.